Clinical trial · Interventional
Feasibility of Pet-scan at Day 1 of Brachytherapy for Patients With Cervical Cancer
Feasibility of PET-scan Carried Out at Day 1 of Brachytherapy for Patients With Locally Advanced Cervical Cancer Treated Initially by Concomitant Radio-chemotherapy
NCT03315351CI-TRIAL-00105493TEP-CuriecompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Interventional, exploratory, prospective and monocentric study which aim to study the feasibility of brachytherapy using a PET-scan
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Brachytherapy | Procedure | — | UNRESOLVED |
| PET-scan | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Study Procedure
- description
- Brachytherapy. PET-scan.
- interventionNames
- Procedure: Brachytherapy
- Other: PET-scan
Primary outcomes (4)
- measure
- Feasibility of "TEP-Curie" (Brachytherapy driven by PET-scan) in terms of realized exams
- timeFrame
- 4 months
- description
- Concerning this outcome, the success in terms of feasibility will be the possibility of realizing the TEP-Curie exam
- measure
- Feasibility of "TEP-Curie" (Brachytherapy driven by PET-scan) regarding the possibility to define HR-CTV target volume (High-Risk Clinical Target Volume)
- timeFrame
- 4 months
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient suffering from a cervical cancer: * squamous-cell carcinoma or adenocarcinoma histologically proven * classified from FIGO 2009 IB2 to IVA stage * Age ≥ 18 years old * Examination by PET-scan and pelvic RMI realized at diagnosis * Examination by negative PET-scan remotely closed and at lymph node level * Surgical lymphadenectomy negative at paraaortic level * Treatment by external radiotherapy (doses between 45 Gy and 50.4 Gy in 1.8 Gy/fractions) and concomitant chemotherapy (at least 4 cures per weeks using platinum salt) done * Scheduled curative treatment by brachytherapy driven by RMI * Affiliation to the National Social Security System * With informed and signed consent before any procedure specific to the study Exclusion Criteria: * Performance status of WHO score \> 2 * Other histology than squamous cell carcinoma or adenocarcinoma * Metastatic patient or paraaortic node positive * Adjuvant radiochemotherapy after the first surgery * Dementia or psychiatric history * Kidney failure * Diabet * Chronic inflammatory bowel disease * Pelvic and/or vesicoureteral surgery history * Pelvic irradiation history * Other active neoplasia or \< 5 years old, except for basocellular carcinoma that can be locally treated * Contraindication to one of the following procedure : RMI, PET-scan, general anesthesia * Radiosensitive disease (Fragile X syndrome, Huntington's chorea, Xeroderma Pigmentosum, connective tissue disease) or signs of radiosensitivity. * Treatment with palliative intent * Pregnant or breastfeeding women * Patient Under guardianship or tutorship
References
Publications (0)
Data not yet available
No reference posted for this study.